Vanda Alice Lennon

Vanda Alice Lennon's AcademicInfluence.com Rankings

Vanda Alice Lennon

Biology

#5052

World Rank

#7439

Historical Rank

Immunology

#222

World Rank

#231

Historical Rank

biology Degrees

Download Badge

Biology

Vanda Alice Lennon's Degrees

PhD Immunology University of California, San Francisco
Bachelors Biology University of California, Berkeley

Similar Degrees You Can Earn

Best Online Bachelor's in Biology 2026

Why Is Vanda Alice Lennon Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Vanda Alice Lennon's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion (2002) (2964)
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis (2004) (2780)
Revised diagnostic criteria for neuromyelitis optica (2006) (2511)
IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel (2005) (2026)
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion (2002) (1995)
The spectrum of neuromyelitis optica (2007) (1939)
Brain abnormalities in neuromyelitis optica. (2006) (681)
Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. (2007) (672)
Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. (2006) (669)
Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies. (2000) (601)
Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis (2006) (555)
Neuromyelitis optica and non organ-specific autoimmunity. (2008) (555)
Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. (1995) (547)
Antibody to acetylcholine receptor in myasthenia gravis (1976) (522)
CRMP‐5 neuronal autoantibody: Marker of lung cancer and thymoma‐related autoimmunity (2001) (501)
Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies (1998) (478)
Steroid-responsive encephalopathy associated with autoimmune thyroiditis. (2006) (456)
Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica (2007) (436)
Postural orthostatic tachycardia syndrome: the Mayo clinic experience. (2007) (421)
Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. (1999) (408)
Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody (2004) (398)
Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis (2018) (384)
Autoimmune epilepsy: clinical characteristics and response to immunotherapy. (2012) (327)
Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study (2013) (317)
Brief report: inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia. (1994) (313)
NMO-IgG predicts the outcome of recurrent optic neuritis (2008) (312)
Serologic diagnosis of NMO (2012) (310)
Aquaporin-4–binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2 (2008) (301)
Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome (2004) (300)
Experimental autoimmune myasthenia: A model of myasthenia gravis in rats and guinea pigs (1975) (300)
Antibody to acetylcholine receptor in myasthenia gravis (1976) (300)
Amphiphysin autoimmunity: Paraneoplastic accompaniments (2005) (294)
Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy: A Novel Meningoencephalomyelitis. (2016) (290)
A secondary progressive clinical course is uncommon in neuromyelitis optica (2007) (286)
Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: Analysis of 102 patients (2017) (283)
CNS aquaporin-4 autoimmunity in children (2008) (279)
Neuromyelitis optica unique area postrema lesions (2011) (277)
Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes (2011) (265)
Anti‐neuronal nuclear autoantibody type 2: Paraneoplastic accompaniments (2003) (262)
Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders (2008) (257)
EXPERIMENTAL AUTOIMMUNE MYASTHENIA GRAVIS AND MYASTHENIA GRAVIS: BIOCHEMICAL AND IMMUNOCHEMICAL ASPECTS * (1976) (252)
Clinical, magnetic resonance imaging, and electroencephalographic findings in paraneoplastic limbic encephalitis. (2003) (251)
Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis (1978) (239)
Ultrastructural localization of the acetylcholine receptor in myasthenia gravis and in its experimental autoimmune model (1977) (235)
Epidemiology of aquaporin‐4 autoimmunity and neuromyelitis optica spectrum (2016) (234)
Immunoglobulins promote remyelination in the central nervous system (1990) (225)
Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG–Associated Disorders (2018) (224)
Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome. (2018) (215)
Neuronal nicotinic ACh receptor antibody in subacute autonomic neuropathy and cancer‐related syndromes (1998) (213)
Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine recepotr antibodies (1976) (212)
Stiff-man syndrome and variants: clinical course, treatments, and outcomes. (2012) (209)
Clinical Correlations of Antibodies That Bind, Block, or Modulate Human Acetylcholine Receptors in Myasthenia Gravis a (1987) (209)
Glutamic acid decarboxylase autoimmunity with brainstem, extrapyramidal, and spinal cord dysfunction. (2006) (207)
Dystonia and cerebellar atrophy in Cacna1a null mice lacking P/Q calcium channel activity (2001) (205)
Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders. (2015) (198)
Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica (2013) (196)
Myasthenia gravis induced by monoclonal antibodies to acetylcholine receptors (1980) (194)
Autoantibody Profiles and Neurological Correlations of Thymoma (2004) (194)
Expanded phenotypes and outcomes among 256 LGI1/CASPR2‐IgG–positive patients (2017) (194)
The spectrum of autoimmune autonomic neuropathies (2003) (192)
Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP‐5‐IgG (2003) (189)
Paraneoplastic chorea associated with CRMP‐5 neuronal antibody and lung carcinoma (2002) (186)
Higher autoantibody levels and recognition of a linear NH2-terminal epitope in the autoantigen GAD65, distinguish stiff-man syndrome from insulin-dependent diabetes mellitus (1994) (184)
Aquaporin-4 autoantibodies in a paraneoplastic context. (2008) (183)
Utility of an immunotherapy trial in evaluating patients with presumed autoimmune epilepsy (2014) (181)
Glycine receptor autoimmune spectrum with stiff-man syndrome phenotype. (2013) (180)
Antibody to acetylcholine receptor in myasthenia gravis: Prevalence, clinical correlates, and diagnostic value (1998) (179)
Insights from LGI1 and CASPR2 potassium channel complex autoantibody subtyping. (2013) (176)
EXPERIMENTAL AUTOIMMUNE MYASTHENIA GRAVIS: CELLULAR AND HUMORAL IMMUNE RESPONSES * (1976) (175)
Voltage-gated potassium channel autoimmunity mimicking creutzfeldt-jakob disease. (2008) (173)
Enteric neuronal autoantibodies in pseudoobstruction with small-cell lung carcinoma. (1991) (173)
Beneficial plasma exchange response in central nervous system inflammatory demyelination. (2011) (172)
New Purkinje cell antibody (PCA‐2): Marker of lung cancer–related neurological autoimmunity (2000) (171)
Clinical spectrum of voltage-gated potassium channel autoimmunity (2008) (171)
Intractable vomiting as the initial presentation of neuromyelitis optica (2010) (170)
Pathological mechanisms in experimental autoimmune myasthenia gravis. I. Immunogenicity of syngeneic muscle acetylcholine receptor and quantitative extraction of receptor and antibody-receptor complexes from muscles of rats with experimental automimmune myasthenia gravis (1976) (169)
Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders (2009) (168)
Clinical Features and Treatment Outcomes of Necrotizing Autoimmune Myopathy. (2015) (167)
Identification of Three Subunits of the High Affinity ω-Conotoxin MVIIC-sensitive Ca2+ Channel* (1996) (166)
Aquaporin-4 autoimmunity (2015) (163)
ANNA‐3 anti‐neuronal nuclear antibody: Marker of lung cancer‐related autoimmunity (2001) (157)
Paraneoplastic gastrointestinal motor dysfunction: clinical and laboratory characteristics (2001) (156)
Autoimmune dementia: clinical course and predictors of immunotherapy response. (2010) (155)
Chronic pain as a manifestation of potassium channel-complex autoimmunity (2012) (154)
THE MOTOR END PLATE IN MYASTHENIA GRAVIS AND IN EXPERIMENTAL AUTOIMMUNE MYASTHENIA GRAVIS. A QUANTITATIVE ULTRASTRUCTURAL STUDY * (1976) (154)
Ganglionic acetylcholine receptor autoantibody: oncological, neurological, and serological accompaniments. (2009) (150)
Subunit Heterogeneity in N-type Ca Channels (*) (1996) (150)
Immunization with neuronal nicotinic acetylcholine receptor induces neurological autoimmune disease. (2003) (150)
DPPX potassium channel antibody (2014) (149)
Ion channel and striational antibodies define a continuum of autoimmune neuromuscular hyperexcitability (2002) (131)
Effects of neuromyelitis optica–IgG at the blood–brain barrier in vitro (2016) (128)
Paraneoplastic cerebellar degeneration: a clinical comparison of patients with and without Purkinje cell cytoplasmic antibodies. (1990) (128)
Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica (2009) (127)
Neuromyelitis optica-IgG (aquaporin-4) autoantibodies in immune mediated optic neuritis (2009) (122)
Thymic B lymphocyte clones from patients with myasthenia gravis secrete monoclonal striational autoantibodies reacting with myosin, alpha actinin, or actin (1986) (122)
Radioimmunoassay for glutamic acid decarboxylase (GAD65) autoantibodies as a diagnostic aid for stiff-man syndrome and a correlate of susceptibility to type 1 diabetes mellitus. (1998) (119)
Remyelination by Oligodendrocytes Stimulated by Antiserum to Spinal Cord (1987) (118)
Kelch-like Protein 11 Antibodies in Seminoma-Associated Paraneoplastic Encephalitis. (2019) (117)
Gynecologic cancer in patients with subacute cerebellar degeneration predicted by anti-Purkinje cell antibodies and limited in metastatic volume. (1990) (117)
Positron emission tomography-computed tomography in paraneoplastic neurologic disorders: systematic analysis and review. (2010) (114)
Passive Transfer of Autoimmune Autonomic Neuropathy to Mice (2004) (113)
ULTRASTRUCTURAL LOCALIZATION OF IMMUNE COMPLEXES (IgG and C3) AT THE END‐PLATE IN EXPERIMENTAL AUTOMMUNE MYASTHENIA GRAVIS (1977) (112)
END‐PLATE POTENTIALS IN EXPERIMENTAL AUTOIMMUNE MYASTHENIA GRAVIS IN RATS * (1976) (111)
Paraneoplastic isolated myelopathy (2011) (111)
Autoantibodies bind solubilized calcium channel-omega-conotoxin complexes from small cell lung carcinoma: a diagnostic aid for Lambert-Eaton myasthenic syndrome. (1989) (110)
Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells. (2009) (108)
GABAB receptor autoantibody frequency in service serologic evaluation (2013) (108)
Paraneoplastic anti-Purkinje and type I anti-neuronal nuclear autoantibodies bind selectively to central, peripheral, and autonomic nervous system cells. (1991) (108)
MONOCLONAL AUTOANTIBODIES TO ACETYLCHOLINE RECEPTORS: EVIDENCE FOR A DOMINANT IDIORPE AND REQUIREMENT OF COMPLEMENT FOR PATHOGENICITY * (1981) (107)
Absence of cortical demyelination in neuromyelitis optica (2010) (105)
Sleep manifestations of voltage-gated potassium channel complex autoimmunity. (2011) (101)
Predictive models in the diagnosis and treatment of autoimmune epilepsy (2017) (99)
Glucose-regulated protein 78 autoantibody associates with blood-brain barrier disruption in neuromyelitis optica (2017) (99)
Serologic profile of myasthenia gravis and distinction from the Lambert-Eaton myasthenic syndrome (1997) (98)
Region of peptide 125-147 of acetylcholine receptor alpha subunit is exposed at neuromuscular junction and induces experimental autoimmune myasthenia gravis, T-cell immunity, and modulating autoantibodies. (1985) (97)
Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder (2020) (94)
Frequency of seronegativity in adult‐acquired generalized myasthenia gravis (2007) (94)
Autoimmune GFAP astrocytopathy: Prospective evaluation of 90 patients in 1 year (2018) (94)
Recombinant human acetylcholine receptor alpha-subunit induces chronic experimental autoimmune myasthenia gravis. (1991) (93)
EXPERIMENTAL AUTOIMMUNE MYASTHENIA GRAVIS: A SEQUENTIAL AND QUANTITATIVE STUDY OF THE NEUROMUSCULAR JUNCTION ULTRASTRUCTURE AND ELECTROPHYSIOLOGIC CORRELATIONS (1976) (92)
Myasthenia gravis with autoimmune autonomic neuropathy (2001) (91)
Diagnosis of neuromyelitis spectrum disorders: comparative sensitivities and specificities of immunohistochemical and immunoprecipitation assays. (2009) (90)
STIFF-PERSON SYNDROME WITH AMPHIPHYSIN ANTIBODIES: DISTINCTIVE FEATURES OF A RARE DISEASE (2009) (90)
Effects of age and sex on aquaporin-4 autoimmunity. (2012) (90)
The case for a descriptive generic nomenclature (1994) (89)
Passively transferred experimental autoimmune myasthenia gravis (1979) (89)
Idiopathic autonomic neuropathy: comparison of cases seropositive and seronegative for ganglionic acetylcholine receptor antibody. (2004) (89)
OSMS is NMO, but not MS: proven clinically and pathologically (2006) (88)
Autoimmunity in the Lambert-Eaton myasthenic syndrome. (1982) (88)
Appearance of neurons in the developing chick gut (1995) (88)
Autoimmune chorea in adults (2013) (87)
Immunoglobulins reactive with myelin basic protein promote CNS remyelination (1996) (87)
Serologic profiles aiding the diagnosis of autoimmune gastrointestinal dysmotility. (2008) (87)
NMO-IgG: A Specific Biomarker for Neuromyelitis Optica (2006) (84)
Investigation of the KIR4.1 potassium channel as a putative antigen in patients with multiple sclerosis: a comparative study (2014) (84)
Autoimmune gastrointestinal dysmotility treated successfully with pyridostigmine. (2006) (83)
IgLON5 antibody (2017) (83)
Neurological autoimmunity targeting aquaporin-4 (2010) (83)
Autonomic dysfunction in the Lambert-Eaton myasthenic syndrome (1998) (81)
Lambert‐eaton myasthenic syndrome immunoglobulins react with multiple types of calcium channels in small‐cell lung carcinoma (1996) (78)
Molecular diversity of neuronal-type calcium channels identified in small cell lung carcinoma. (1992) (78)
Genetic control of experimental autoimmune myasthenia gravis in mice. I. Lymphocyte proliferative response to acetylcholine receptors is under H-2-linked Ir gene control. (1979) (77)
Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Autoantibody Status Predict Outcome of Recurrent Optic Neuritis. (2018) (76)
Purkinje cell cytoplasmic autoantibody type 1 accompaniments: the cerebellum and beyond. (2011) (76)
P/Q‐ and N‐type calcium‐channel antibodies: Oncological, neurological, and serological accompaniments (2016) (75)
Paraneoplastic jaw dystonia and laryngospasm with antineuronal nuclear autoantibody type 2 (anti-Ri). (2010) (75)
CSF complements serum for evaluating paraneoplastic antibodies and NMO-IgG (2011) (75)
Clinical utility of testing AQP4-IgG in CSF (2016) (74)
Neural antigen‐specific autoimmune disorders (2012) (73)
Immunopharmacological disease: a break in tolerance to receptor sites. (1971) (73)
Experimental autoimmune autonomic neuropathy. (2003) (73)
Antagonism of voltage-gated calcium channels in small cell carcinomas of patients with and without Lambert-Eaton myasthenic syndrome by autoantibodies omega-conotoxin and adenosine. (1988) (71)
Immunologic properties of the main encephalitogenic peptide from the basic protein of human myelin. (1970) (69)
AQP4 autoantibody assay performance in clinical laboratory service (2014) (68)
Transitory expression of Thy-1 antigen in skeletal muscle development (1977) (66)
Expanded Clinical Phenotype, Oncological Associations, and Immunopathologic Insights of Paraneoplastic Kelch-like Protein-11 Encephalitis. (2020) (65)
Hu antigen specificities of ANNA-I autoantibodies in paraneoplastic neurological disease. (1999) (64)
End‐plate voltage‐gated sodium channels are lost in clinical and experimental myasthenia gravis (1998) (64)
The laboratory diagnosis of mild myasthenia gravis (1982) (63)
IMMUNOTHERAPY-RESPONSIVE DEMENTIAS AND ENCEPHALOPATHIES (2010) (63)
Astrocytic autoantibody of neuromyelitis optica (NMO-IgG) binds to aquaporin-4 extracellular loops, monomers, tetramers and high order arrays. (2013) (63)
Neural Autoantibody Profile of Primary Achalasia (2010) (62)
Selected IgG rapidly induces Lambert–Eaton myasthenic syndrome in mice: Complement independence and EMG abnormalities (1988) (62)
Autoimmune aquaporin-4 myopathy in neuromyelitis optica spectrum. (2014) (61)
Childhood onset of stiff-man syndrome. (2013) (61)
Autoimmune myelopathy associated with collapsin response‐mediator protein‐5 immunoglobulin G (2008) (60)
Autoimmune CRMP5 neuropathy phenotype and outcome defined from 105 cases (2018) (59)
GENETIC CONTROL OF AUTOIMMUNITY TO ACETYLCHOLINE RECEPTORS: ROLE OF Ia MOLECULES * (1981) (59)
Seroprevalence of aquaporin-4-IgG in a northern California population representative cohort of multiple sclerosis. (2014) (59)
Autoimmune paraneoplastic cerebellar degeneration (1988) (58)
The neurologic significance of celiac disease biomarkers (2014) (58)
Paraneoplastic autoantibodies (1994) (57)
Neuronal voltage-gated potassium channel complex autoimmunity in children. (2011) (57)
Evidence against acetylcholine receptor having a main immunogenic region as target for autoantibodies in myasthenia gravis (1989) (56)
Neurectoderm markers retained in phenotypical skeletal muscle cells arising from a glial cell line (1979) (56)
Astrocyte-microglia interaction drives evolving neuromyelitis optica lesion. (2020) (55)
Brain-derived fibroblast growth factor: identity with a fragment of the basic protein of myelin. (1978) (54)
Paraneoplastic motor neuron disease with type 1 Purkinje cell antibodies (1998) (54)
Paraneoplastic dysmotility: loss of interstitial cells of Cajal (2002) (53)
Predictors of neural-specific autoantibodies and immunotherapy response in patients with cognitive dysfunction (2018) (52)
N-methyl-D-aspartate receptor autoimmune encephalitis presenting with opsoclonus-myoclonus: treatment response to plasmapheresis. (2011) (52)
Intractable nausea and vomiting from autoantibodies against a brain water channel. (2013) (52)
Autoantibodies in paraneoplastic cerebellar degeneration bind to cytoplasmic antigens of Purkinje cells in humans, rats and mice and are of multiple immunoglobulin classes (1988) (52)
Paraneoplastic anti-neuronal nuclear IgG autoantibodies (type I) localize antigen in small cell lung carcinoma. (1991) (51)
Striational autoantibodies: quantitative detection by enzyme immunoassay in myasthenia gravis, thymoma, and recipients of D-penicillamine or allogeneic bone marrow. (1988) (51)
Identification and Cloning of Putative Human Neuronal Voltage-Gated Calcium Channel γ-2 and γ-3 Subunits: Neurologic Implications (1999) (51)
Neural Autoantibody Clusters Aid Diagnosis of Cancer (2014) (50)
Paraneoplastic neuromyelitis optica spectrum disorder associated with metastatic carcinoid expressing aquaporin-4. (2014) (50)
Immunotherapy trial as diagnostic test in evaluating patients with presumed autoimmune gastrointestinal dysmotility (2014) (50)
An outbreak of neurological autoimmunity with polyradiculoneuropathy in workers exposed to aerosolised porcine neural tissue: a descriptive study (2010) (49)
Microtubule‐associated protein 1B: Novel paraneoplastic biomarker (2017) (49)
Genetic control of experimental autoimmune myasthenia gravis in mice. III. Ia molecules mediate cellular immune responsiveness to acetylcholine receptors. (1982) (49)
Aquaporin 4 IgG serostatus and outcome in recurrent longitudinally extensive transverse myelitis. (2014) (48)
Frequency of Synaptic Autoantibody Accompaniments and Neurological Manifestations of Thymoma. (2016) (48)
Optic Neuritis In the Era of Biomarkers. (2019) (47)
The distribution of myelin-associated glycoprotein and myelin basic protein in actively demyelinating multiple sclerosis lesions (1984) (47)
Pathogenic implications of cerebrospinal fluid barrier pathology in neuromyelitis optica (2017) (47)
Syndrome of inappropriate antidiuresis may herald or accompany neuromyelitis optica (2011) (46)
Diagnostic utility of aquaporin-4 in the analysis of active demyelinating lesions (2015) (46)
Autoimmune AQP4 channelopathies and neuromyelitis optica spectrum disorders. (2016) (46)
Neurological autoimmunity and immune checkpoint inhibitors: Autoantibody profiles and outcomes. (2020) (46)
How myasthenia gravis alters the safety factor for neuromuscular transmission (2008) (45)
Nicotinic Acetylcholine Receptors of Muscle and Neuronal (α7) Types Coexpressed in a Small Cell Lung Carcinoma (1997) (45)
Psychiatric Autoimmunity: N-Methyl-D-Aspartate Receptor IgG and Beyond. (2015) (45)
Congenital myasthenia gravis in 13 smooth fox terriers. (1983) (45)
Detection of antibodies to the basic protein of human myelin by radioimmunoassay and immunofluorescence. (1971) (44)
Evolution of longitudinally extensive transverse myelitis in an aquaporin-4 IgG-positive patient (2013) (44)
LGI1 and CASPR2 neurological autoimmunity in children (2018) (44)
Anti-Purkinje cell cytoplasmic and neuronal nuclear antibodies aid diagnosis of paraneoplastic autoimmune neurological disorders. (1989) (43)
Acetylcholine Receptors in Small Cell Carcinomas (1985) (43)
Anti-N-methyl-D-aspartate receptor encephalitis: early treatment is beneficial. (2010) (43)
Demyelination and Remyelination in Murine Viral Encephalomyelitis a (1984) (43)
Psychiatric manifestations of voltage-gated potassium-channel complex autoimmunity. (2011) (42)
EXPERIMENTAL AUTOIMMUNE MYASTHENIA: CLINICAL, NEUROPHYSIOLOGIC, AND PHARMACOLOGIC ASPECTS * (1976) (42)
Autoimmune preganglionic sympathectomy induced by acetylcholinesterase antibodies. (1990) (41)
Thy-1: a differentiation marker of potential mammary myoepithelial cells in vitro. (1978) (41)
Calcium Channel and Related Paraneoplastic Disease Autoantibodies (1996) (40)
Clinical utility of testing AQP 4-IgG in CSF Guidance for physicians (40)
Muscle specific kinase autoimmune myasthenia gravis in children: A case series (2013) (40)
Paraneoplastic IgG striational autoantibodies produced by clonal thymic B cells and in serum of patients with myasthenia gravis and thymoma react with titin. (1992) (39)
Neurologic Autoimmunity in the Era of Checkpoint Inhibitor Cancer Immunotherapy. (2019) (39)
Whole-body tremulousness: isolated generalized polymyoclonus. (2007) (38)
Purification and biochemical characterization of nicotinic acetylcholine receptors of human muscle. (1982) (38)
Genetic control of experimental autoimmune myasthenia gravis in mice. II. Lymphocyte proliferative response to acetylcholine receptor is dependent on Lyt-1+23- cells. (1979) (38)
Striational antibodies in a paraneoplastic context (2013) (37)
Myasthenia, thymoma, presynaptic antibodies, and a continuum of neuromuscular hyperexcitability (1999) (37)
Glycine receptor modulating antibody predicting treatable stiff-person spectrum disorders (2018) (37)
Autoantibody-induced internalization of CNS AQP4 water channel and EAAT2 glutamate transporter requires astrocytic Fc receptor (2017) (37)
Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG (2003) (36)
Role of T lymphocytes in the pathogenesis of experimental autoimmune encephalomyelitis (1973) (36)
Clinical remission following plasmapheresis and corticosteroid treatment in a dog with acquired myasthenia gravis. (1990) (36)
Paraneoplastic neuronal intermediate filament autoimmunity (2018) (36)
Fulminant autoimmune cortical encephalitis associated with thymoma treated with plasma exchange. (2000) (35)
Immunology of the acetylcholine receptor. (1976) (35)
Activation of muscarinic acetylcholine receptors inhibits cell cycle progression of small cell lung carcinoma. (1991) (35)
Binding of 125 I myelin basic protein by serum and cerebrospinal fluid. (1972) (34)
Reversible extralimbic paraneoplastic encephalopathies with large abnormalities on magnetic resonance images. (2009) (34)
Immunoglobulins and complement in demyelination induced in mice by Theiler's virus. (1988) (34)
Peripherin-IgG association with neurologic and endocrine autoimmunity. (2010) (34)
Activation of M3 muscarinic acetylcholine receptors inhibits voltage-dependent calcium influx in small cell lung carcinoma. (1990) (33)
Subacute sensory neuronopathy associated with small cell lung carcinoma: diagnosis aided by autoimmune serology. (1988) (33)
Autoantibodies to acetylcholine receptors in myasthenia gravis. (1983) (33)
Paraneoplastic movement disorder in a patient with non‐Hodgkin's lymphoma and CRMP‐5 autoantibody (2003) (33)
α‐Bungarotoxin Binds to Human Acetylcholine Receptor α‐Subunit Peptide 185–199 in Solution and Solid Phase but Not to Peptides 125–147 and 389–409 (1990) (32)
Evidence of aquaporin involvement in human central pontine myelinolysis (2013) (32)
Paraneoplastic autoimmunity and small‐cell lung cancer: Neurological and serological accompaniments (2019) (32)
Myasthenia gravis in the cat. (1988) (32)
Binding of encephalitogenic basic protein by serum alpha-globulins. (1970) (32)
Autoimmune gait disturbance accompanying adaptor protein-3B2-IgG (2019) (31)
Extratemporal EEG and MRI findings in ANNA-1 (anti-Hu) encephalitis (2011) (31)
The immunopathology of myasthenia gravis. (1978) (31)
Myasthenia gravis in two cats. (1983) (31)
Reduced muscle acetylcholine sensitivity in rats immunised with acetylcholine receptor (1976) (30)
Seronegativity for type 1 antineuronal nuclear antibodies ('anti‐Hu') in subacute sensory neuronopathy patients without cancer (1993) (30)
Enteric GABA‐containing nerves projecting to the guinea‐pig inferior mesenteric ganglion modulate acetylcholine release. (1993) (29)
Anesthesia for an unsuspected Lambert-Eaton myasthenic syndrome with autoantibodies and occult small cell lung carcinoma. (1992) (29)
Elevated LGI1‐IgG CSF index predicts worse neurological outcome (2018) (28)
Erratum: Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion (Nature Medicine (2002) 8 (793-800)) (2002) (28)
Autoimmune septin-5 cerebellar ataxia (2018) (28)
The complement C3‐C3aR pathway mediates microglia–astrocyte interaction following status epilepticus (2020) (28)
Endoplasmic Reticulum Membrane-sorting Protein of Lymphocytes (BAP31) Is Highly Expressed in Neurons and Discrete Endocrine Cells (2001) (28)
Pseudopseudoseizures: conditions that may mimic psychogenic non-epileptic seizures. (2011) (28)
Paraneoplastic dysmotility: loss of interstitial cells of Cajal. (2002) (27)
Paraneoplastic neurological autoimmunity associated with ANNA-1 autoantibody and thymoma. (2002) (27)
Myasthenogenicity of human acetylcholine receptor synthetic alpha-subunit peptide 125-147 does not require intramolecular disulfide cyclization. (1987) (26)
Antigen, host and adjuvant requirements for induction of hyperacute experimental autoimmune encephalomyelitis (1976) (26)
Neuromyelitis optica IgG serostatus in fulminant central nervous system inflammatory demyelinating disease. (2009) (26)
Neurologic autoimmunity and immune checkpoint inhibitors (2020) (26)
Clinically disparate stiff-person syndrome with GAD65 autoantibody in a father and daughter (2003) (26)
Paraneoplastic optic neuropathy and cerebellar ataxia with small cell carcinoma of the lung. (2001) (25)
Properties of nicotinic acetylcholine receptors isolated by affinity chromatography on monoclonal antibodies. (1980) (25)
Polyglutamine repeats of spinocerebellar ataxia 6 impair the cell-death-preventing effect of CaV2.1 Ca2+ channel—loss-of-function cellular model of SCA6 (2004) (25)
Myasthenia gravis, thymoma, and intestinal pseudo-obstruction: a case report and review. (2003) (25)
Intestinal pseudo‐obstruction, type 1 anti‐neuronal nuclear antibodies and small‐cell carcinoma of the lung (1993) (24)
Neuronal Ganglionic Acetylcholine Receptor Autoimmunity (2003) (24)
Potassium channel complex autoimmunity induced by inhaled brain tissue aerosol (2012) (23)
Morphological characteristics and immunohistochemical detection of nicotinic acetylcholine receptors on intestinofugal afferent neurones in guinea‐pig colon (2003) (23)
Selective Complexing of Acetylcholinesterase in Brain by Intravenously Administered Monoclonal Antibody (1990) (23)
Death of intermediolateral spinal cord neurons follows selective, complement-mediated destruction of peripheral preganglionic sympathetic terminals by acetylcholinesterase antibodies (1993) (22)
Eliminating false‐positive results in serum tests for neuromuscular autoimmunity (2010) (22)
Neuronal autoantibody titers in the course of small-cell lung carcinoma and platinum-associated neuropathy (1999) (22)
Human monoclonal striational autoantibodies isolated from thymic B lymphocytes of patients with myasthenia gravis use VH and VL gene segments associated with the autoimmune repertoire (1992) (22)
Hydrocephalus in neuromyelitis optica (2014) (22)
Depression of complex bioelectric discharges in cerebral tissue cultures by thermolabile complement-dependent serum factors (1975) (21)
ITPR1 autoimmunity: Frequency, neurologic phenotype, and cancer association (2017) (21)
Exchange transfusion in neonatal myasthenia gravis (1981) (21)
STIFF EYES IN STIFF-PERSON SYNDROME (2008) (21)
Acetylcholine receptor autoantibody secretion by thymocytes: Relationship to myasthenia gravis (1997) (21)
Herpes simplex virus 1 encephalitis associated with voltage-gated calcium channel autoimmunity (2015) (20)
Synthesis of an antigenic site of native acetylcholine receptor peptide 159-169 of Torpedo acetylcholine receptor alpha-chain. (1985) (20)
Myasthenia Gravis and Related Disorders: Experimental and Clinical Aspects (1993) (19)
Congenital canine myasthenia gravis: I. Deficient junctional acetylcholine receptors (1984) (19)
Absence of Brain Antibodies in Senile Dementia (1970) (18)
Immunofluorescence Analysis of Surface Acetylcholine Receptors on Muscle: Modulation by Auto-Antibodies (1978) (18)
Comment on “Thiamine Deficiency Promotes T Cell Infiltration in Experimental Autoimmune Encephalomyelitis: The Involvement of CCL2” (2014) (18)
Bilateral autoimmune optic neuritis and vitreitis related to CRMP-5-IgG: intravitreal triamcinolone acetonide therapy of four eyes (2008) (18)
Differentiation of skeletal muscle from dissociated optic nerve cells Immunocytochemical observations (1981) (18)
Identification and cloning of putative human neuronal voltage-gated calcium channel gamma-2 and gamma-3 subunits: neurologic implications. (1999) (18)
GABAA receptor autoimmunity (2019) (18)
Thy-1 antigen expression on rat brain cell lines (1978) (17)
Neurochondrin neurological autoimmunity (2019) (17)
Glucocorticoids Target Ependymal Glia and Inhibit Repair of the Injured Spinal Cord (2019) (16)
Clinical‐pathologic correlations in voltage‐gated Kv1 potassium channel complex‐subtyped autoimmune painful polyneuropathy (2017) (16)
Rare combination of myasthenia and motor neuronopathy, responsive to Msc‐Ntf stem cell therapy (2014) (16)
Lymphocytes binding basic protein of myelin; cytophilic serum antibody and effect of adjuvant. (1973) (15)
Tests for pernicious anemia: serum intrinsic factor blocking antibody. (1983) (15)
Autoimmune/Paraneoplastic Encephalitis Antibody Biomarkers: Frequency, Age, and Sex Associations (2021) (15)
Hyperacute autoimmune encephalomyelitis induced by a synthetic autoantigen (1977) (15)
Autoimmune form of myasthenia gravis in a juvenile Yorkshire Terrier x Jack Russell Terrier hybrid contrasted with congenital (non-autoimmune) myasthenia gravis of the Jack Russell. (1980) (14)
Metastatic chondroblastoma with elevated creatine kinase and paraneoplastic neurologic autoimmunity. (2003) (14)
An avidin-biotin-peroxidase assay to detect synthetic peptides bound to polystyrene plates. (1991) (14)
Serum Antibodies and Monoclonal Antibodies Secreted by Thymic B‐Cell Clones from Patients with Myasthenia Gravis Define Striational Antigens a (1987) (14)
Definition of Myasthenogenic Sites of the Human Acetylcholine Receptor Using Synthetic Peptides a (1987) (14)
Neuromuscular transmission in nude mice bearing oat cell tumors from Lambert-Eaton myasthenic syndrome. (1982) (13)
Leucine Zipper 4 Autoantibody: A Novel Germ Cell Tumor and Paraneoplastic Biomarker (2021) (13)
NMDAR encephalitis: which specimens, and the value of values (2014) (13)
Immunological responses of guinea pigs to a synthetic autoantigen of brain (1974) (13)
Nicotinic acetylcholine receptors of muscle and neuronal (alpha7) types coexpressed in a small cell lung carcinoma. (1997) (13)
Neural Autoantibody Evaluation in Functional Gastrointestinal Disorders: A Population-Based Case–Control Study (2011) (12)
Identification of three extended antibody-binding segments in recombinant human muscle acetylcholine receptor alpha subunit extracellular domain 1-210. (1991) (12)
A 17-Mer self-peptide of acetylcholine receptor binds to B cell MHC class II, activates helper T cells, and stimulates autoantibody production and electrophysiologic signs of myasthenia gravis. (1997) (12)
Congenital canine myasthenia gravis: II. Acetylcholine receptor metabolism (1984) (12)
Humoral and cell-mediated immune responses of Lewis rats to syngeneic basic protein of myelin. (1974) (12)
Guamanian neurodegenerative disease (1997) (12)
Paraneoplastic cerebellar autoantibodies associated with gynecological cancer bind to myenteric plexus neurons (1991) (11)
Mouse T lymphocyte response to acetylcholine receptor determined by T cell receptor for antigen V beta gene products recognizing Mls-1a. (1991) (11)
Stability of bombesin in serum, plasma, urine, and culture media. (1985) (11)
A CHRNE frameshift mutation causes congenital myasthenic syndrome in young Jack Russell Terriers (2015) (11)
Muscle acetylcholine receptors complexed with autologous IgG reflect seropositivity but not necessarily in vivo binding (1992) (11)
Collapsin Response-Mediator Protein 5-Associated Retinitis, Vitreitis, and Optic Disc Edema. (2020) (10)
Neuronal calcium channel autoantibodies coexisting with type 1 Purkinje cell cytoplasmic autoantibodies (PCA-1 or "anti-Yo") (1998) (10)
Myasthenia gravis: diagnosis by assay of serum antibodies. (1982) (10)
Gastrointestinal hypomotility with loss of enteric nicotinic acetylcholine receptors: active immunization model in mice (2013) (10)
Do calcium channel autoantibodies cause cerebellar ataxia with Lambert–Eaton syndrome? (2003) (10)
Radiation treatment for thymoma in a dog. (1987) (10)
Cardiac and Respiratory Complications of Necrotizing Autoimmune Myopathy. (2020) (10)
The Prevalence of Electrophysiological and Immunological Abnormalities in Asymptomatic Relatives of Patients with Myasthenia Gravis a (1987) (10)
Purkinje cell cytoplasmic antibody type I (anti-Yo): predictive of gastrointestinal adenocarcinomas in men (2017) (10)
Contactin-1 autoimmunity Serologic, neurologic, and pathologic correlates (9)
Selective destruction of preganglionic sympathetic nerves by antibodies to acetylcholinesterase. (1991) (9)
Experimental Arthritis in Thymectomized Rats with an Impaired Humoral Immune Response (1973) (9)
Humoral pattern II multiple sclerosis pathology not associated with neuromyelitis Optica IgG. (2009) (9)
The detection of autoantibody-forming cells. II. Cells in lymph nodes and central nervous system containing antibody to myelin basic protein. (1972) (9)
Reversible Paraneoplastic Tonic Pupil with PCA-Tr IgG and Hodgkin Lymphoma (2012) (9)
Characterisation of TRIM46 autoantibody-associated paraneoplastic neurological syndrome (2021) (9)
AQP4-IgG immunoprecipitation assay optimization. (2009) (9)
Population-Based Epidemiology Study of Paraneoplastic Neurologic Syndromes (2021) (8)
Mutated cancer autoantigen implicated cause of paraneoplastic myasthenia gravis (2018) (8)
Enzyme immunoassay of anti‐human acetylcholine receptor autoantibodies in patients with myasthenia gravis reveals correlation with striational autoantibodies (1993) (8)
CHRONIC PROGRESSIVE PARANEOPLASTIC SYNDROME WITH PROMINENT BRAINSTEM AND SPINAL CORD INVOLVEMENT, ASSOCIATED WITH TYPE-2 ANTI-NEURONAL NUCLEAR ANTIBODIES (ANNA-2) AND BREAST CARCINOMA: 212 (1995) (8)
Acetylcholine release in diaphragm of rats with chronic experimental autoimmune myasthenia gravis (1978) (8)
Muscle and Neuronal Autoantibody Markers of Thymoma (2003) (8)
Revised diagnostic criteria for neuromyelitis optica (2011) (8)
Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders (2021) (8)
Humoral factors in myasthenia gravis (1975) (7)
AUTOIMMUNE CEREBELLAR DEGENERATION ASSOCIATED WITH CANCER: LOCALIZATION OF PURKINCE CYTOPLASMIC ANTIGEN BY IMMUNO-ELECTRON MICROSCOPY (1986) (7)
Cross-talk between nervous and immune systems in response to injury. (1994) (7)
Paraneoplastic Neurological Autoimmunity (2008) (7)
Voltage‐Dependent Ca2+ Channels in Small Cell Carcinomas Are Blocked by Autoantibodies from Patients with Lambert‐Eaton Myasthenic Syndrome a (1988) (6)
Autoimmune autonomic neuropathy (2002) (6)
Signal recognition particle immunoglobulin g detected incidentally associates with autoimmune myopathy (2016) (6)
Calcium channel autoimmunity: Cerebellar ataxia and lambert‐eaton syndrome coexisting (2018) (6)
Evidence for Structural Dissimilarity in the Neurotransmitter Binding Region of Purified Acetylcholine Receptors from Human Muscle and Torpedo Electric Organ (1986) (6)
Case Report: Innate Immune System Challenge Unleashes Paraneoplastic Neurological Autoimmunity (2020) (6)
Autoantibodies in the Postural Tachycardia Syndrome (P1.272) (2015) (6)
The detection of autoantibody-forming cells. I. An assay for plaque-forming cells to the basic protein of myelin in guinea-pigs. (1972) (6)
Immunotherapy-responsive pain in an abattoir worker with fluctuating potassium channel-complex IgG (2012) (6)
ACh receptor protein drives primary and memory autoantibody responses in chimeric human-SCID mice. (2002) (6)
Membrane array of acetylcholine receptors determines complement-dependent mononuclear phagocytosis in experimental myasthenia gravis (1984) (6)
Autoimmune Myelopathies (2011) (5)
Genetic variation in statin intolerance and a possible protective role for UGT1A1. (2018) (5)
Radiometallating Antibodies and Autoantigenic Peptides (1991) (5)
Lambert-Eaton Syndrome (2009) (5)
Synthetic Peptide of Human Acetylcholine Receptor α‐Subunit Sequence 125‐147 (Methionine 144), a More Potent Autoantigen Than Its Norleucine 144 Analog a (1988) (5)
Nine Residues Influence the Binding of α‐Bungarotoxin in α‐Subunit Region 185–200 of Human Muscle Acetylcholine Receptor (1993) (5)
Complement-mediated lesion of sympathetic ganglia in vitro with acetylcholinesterase antibodies (1999) (4)
Identification of Caveolae-Associated Protein 4 Autoantibodies as a Biomarker of Immune-Mediated Rippling Muscle Disease in Adults (2022) (4)
Purkinje cell cytoplasmic antibody type 1 (anti-Yo) autoimmunity in a child with Down syndrome. (2014) (4)
Asymptomatic lambert–eaton syndrome (2014) (4)
Effects of Age and Sex on Aquaporin-4 Autoimmunity (S60.002) (2012) (3)
GTPase Regulator Associated with Focal Adhesion Kinase 1 (GRAF1) Immunoglobulin‐Associated Ataxia and Neuropathy (2020) (3)
Oncological, Neurological, and Serological Accompaniments (2017) (3)
Spectrum of sublytic astrocytopathy in neuromyelitis optica (2021) (3)
DIFFERENTIATION ANTIGENS OF DEVELOPING AND REGENERATING SKELETAL MUSCLE (1978) (3)
The association of pauciarticular juvenile arthritis and myasthenia gravis. (1991) (3)
Lambert‐Eaton Myasthenic Syndrome: Antigenicity of Recombinant Human P/Q‐type Calcium Channel α1 Subunit Putative Ion Pore Region (Domain IV, S5‐S6) a (1998) (3)
Autoimmune autonomic neuropathy. An immunopharmacological disease. (2002) (2)
Acetylcholine receptor antibodies in tardive dyskinesia. (1994) (2)
Content and release of acetylcholinesterase in skeletal muscle of rats with experimental autoimmune myasthenia gravis (1982) (2)
Swine Influenza Vaccine and Guillain-Barré Syndrome: Lies, Damn Lies, and...-Reply (1986) (2)
Anti‐Neuronal Nuclear Antibody 3 Autoimmunity Targets Dachshund Homolog 1 (2022) (2)
BRAIN TUMOR IMMUNOREACTIVITY WITH TYPE 1 AND TYPE 2 ANTI-NEURONAL NUCLEAR AUTOANTIBODES (1996) (2)
Bilateral autoimmune optic neuritis and vitreitis related to CRMP-5-IgG: intravitreal triamcinolone acetonide therapy of four eyes (2009) (2)
A comparison of tissue-based and recombinant protein–based assays for detecting PCA-Tr/DNER-IgG (2016) (2)
AKR/J gene(s) unlinked to H-2 determines dominant inheritance of lymphocyte hyporesponsiveness to acetylcholine receptor. (1985) (2)
NMDA receptor encephalitis: late treatment also effective. (2014) (2)
Alpha-bungarotoxin binds to human acetylcholine receptor alpha-subunit peptide 185-199 in solution and solid phase but not to peptides 125-147 and 389-409. (1990) (2)
Animal extremists' threats to neurologic research continue (2015) (2)
SRP‐IgG detected incidentally associates with autoimmune myopathy (2015) (2)
IN VITRO DIFFERENTIATION OF SKELETAL MUSCLE FROM A TRITON TUMOR: DOES HUMAN NEUROECTODERM HAVE MYOGENIC POTENTIAL? (1982) (2)
Memory in autoimmune NMDA receptor encephalitis: an issue for B cells and patients. (2016) (2)
DPPX Autoantibody: Frequency, Clinical Accompaniments and Outcomes (S40.001) (2014) (1)
Reply to Rossi et al.: Immunohistopathological findings in neuromyelitis optica concur with immunobiological observations in vitro (2012) (1)
109. Signal recognition particle subunit-specific immunoglobulin G (54 and 72) biomarkers for autoimmune necrotizing or inflammatory myopathy and neoplasia (2012) (1)
Genetic control of experimental autoimmune myasthenia gravis (eamg) in mice. Abstr. (1979) (1)
AQP4-IgG Assays Comparison in Laboratory Clinical Serivce (S63.004) (2014) (1)
Experimental Acetylcholinesterase Autoimmunity (1992) (1)
Author Response. (2016) (1)
A Small Cell Lung Carcinoma Line and Subclone Expressing Nicotinic Acetylcholine Receptors of Muscle and Neuronal Types a (1998) (1)
Necrotizing Autoimmune Myopathy: Comparison of Clinical Features and Treatment Outcomes among Different Etiologies (S17.002) (2015) (1)
Evidence of aquaporin involvement in human central pontine myelinolysis (2013) (1)
Novel redistribution of myosin-containing filaments in cultured keratinocytes identified by a human monoclonal autoantibody (1989) (1)
Myasthenia, thymoma, presynaptic antibodies, and a continuum of neuromuscular hyperexcitability. (1999) (1)
Advances in myasthenia gravis proceedings of the myasthenia gravis foundation medical advisory board, New york, NY, december 3, 1982 (1983) (1)
65 THEILERʼS MURINE ENCEPHALOMYELITIS VIRUS (TMEV) INDUCED DEMYELINATING DISEASE: EFFECT OF TREATMENT WITH MYELIN COMPONENTS (1984) (1)
Positron Emission Tomography-Computed Tomography in Paraneoplastic Neurologic Disorders (2017) (1)
Striational autoantibodies: Paraneoplastic antibodies associated with thymoma and myasthenia gravis (1991) (1)
Double seropositivity for AChR and MuSK autoantibodies in myasthenia gravis (2020) (1)
Adult-Onset Opsoclonus-Myoclonus Syndrome (P04.045) (2012) (1)
Immunogenicity of P/Q-type calcium channel in small cell lung cancer: investigation of alpha1 subunit polyglutamine expansion. (1999) (1)
Antigenicity of synthetic peptides 159-169 and 151-169 of Torpedo acetylcholine receptor alpha chain. (1985) (1)
Anti-purkinje cell cytoplasmic autoantibodies in paraneoplastic cerebellar degeneration are non-species specific and of multiple immunoglobulin classes (1987) (1)
The Stability of Solubilized Mammalian Muscle Acetylcholine Receptors During Purification by Monoclonal Immunoadsorption (1984) (1)
The Incidence and Prevalence of Autoimmune Encephalitis and a comparison to Infectious Encephalitis: A Population-Based Study (P5.401) (2018) (0)
Testing for N-type Voltage Gated Calcium Channel Antibody has Limited Utility in Evaluating Patients With Suspected Lambert-Eaton Myasthenic Syndrome (2022) (0)
WS-21-4 Clinical, electrodiagnostic and serological profile of the Lambert-Eaton myasthenic Syndrome (LES) (1995) (0)
Ma2 Autoantibody-Negative Multifocal Paraneoplastic Neurological Disorder Associated with Metastatic Testicular Cancer. (P4.049) (2015) (0)
neuroimaging clues Paraneoplastic isolated myelopathy : Clinical course and (2011) (0)
Paraneoplastic multifocal neuropathy with anti-CRMP5- and anti-amphiphysin antibodies and myositis preceeding recurrence of a small-cell bladder carcinoma (2005) (0)
Synthetic peptide encompassing human acetylcholine receptor (AChR) α subunit region 125–147 with methionine at position 144 is a potent autoantigen (1987) (0)
Immunohistopathological findings in neuromyelitis optica concur with immunobiological observations in vitro (2012) (0)
Cellular and humoral immune responses to human muscle acetylcholine receptors (1984) (0)
Clinical/ Immunopathological Presentations and Antigen-specific CD8+ T Cell Responses in Paraneoplastic Autoimmune KLHL11 Encephalitis (1185) (2020) (0)
A Mathematical Analysis of Neural Autoantibody Clusters Encountered in Sera of 78,889 Patients Undergoing Comprehensive Paraneoplastic Autoantibody Evaluation (S29.006) (2013) (0)
Medusa Head-Type Neuronal Autoantibody Inositol Triphosphate Receptor-1 (ITPR1)-IgG: Frequency, Clinical Phenotype and Cancer Associations (P5.300) (2016) (0)
Rho GTPase Activating Protein 26 (ARHGAP26)-Igg Autoimmunity: Frequency and Clinical Associations (P3.346) (2016) (0)
Myasthenia gravis and normal lymphocytes respectively transfer memory and primary immune responses specific for human acetylcholine receptor into severe combined immunodeficiency mice (1994) (0)
Nine residues influence the binding of alpha-bungarotoxin in alpha-subunit region 185-200 of human muscle acetylcholine receptor. (1993) (0)
Difficulty Climbing the Stairs (2021) (0)
413. Characterization of four human neuronal voltage-gated calcium channel γ subunit genes (2000) (0)
Effects of Neuromyelitis Optica(NMO)-IgG for leukocyte transmigration at the Blood-Brain Barrier (S46.003) (2015) (0)
Adjuvant activity for alkylamines of immune responses to ovalbumin, myelin basic protein and a tumor. (1974) (0)
Advances in myasthenia gravis proceedings of the myasthenia gravis foundation medical advisory board, New York, NY, December 2, 1983 (1984) (0)
122. Voltage-gated Potassium Channel Autoimmunity Mimicking Creutzfeldt-Jakob Disease (2009) (0)
Purkinje Cell Cytoplasmic Autoantibody Type 1 Accompaniments (2016) (0)
IMMUNOTHERAPY- DEMENTIAS AND (2010) (0)
A Systematic Clinico-Serologic Study of Recurrent Longitudinally Extensive Transverse Myelitis (rTM) and Comparison with NMO (P02.141) (2013) (0)
An Ia.8 restricted T-cell line specific for acetylcholine receptor (1984) (0)
PO27-TH-15 Frequency of false positive neuronal voltage-gated potassium channel antibody detection in serological evaluation for neurological autoimmunity (2009) (0)
Caveolae-Associated Protein (cavin)-4 Autoantibodies in Immune Mediated Rippling Muscle Disease (2022) (0)
Biology of Human Tumors Neural Autoantibody Clusters Aid Diagnosis of Cancer (2014) (0)
CREUTZFELDT-JAKOB DISEASE (CJD) WITH N-TYPE VOL7AGE-GATED Ca2+-CHANNEL ANTIBODIES (N-VGCC Ab) MIMICKING A PARANEOPLASTIC SYNDROME (1998) (0)
The Stiff Child (P01.051) (2013) (0)
The Mayo Clinic Glial Autoimmunity study: Persistence of MOG-IgG seropositivity predicts relapse after ADEM in both children and adults (S13.004) (2018) (0)
Neuronal Intermediate Filament Autoimmunity (S52.005) (2018) (0)
495. A protocol for an animal model for neuroimmunologic psychiatric disease (1996) (0)
74 INTERACTION OF AUTOANTIBODIES WITH ACETYLCHOLINE RECEPTORS IN REGENERATED POSTSYNAPTIC MEMBRANES OF MUSCLE FAILS TO SIGNAL MONONUCLEAR PHAGOCYTOSIS (1984) (0)
Objective and Symptomatic Reversal of Autoimmune Gastrointestinal Dysmotility with Immunotherapy (P05.208) (2012) (0)
The Role of Immunoglobulin G in Neuromyelitis Optica (2010) (0)
The Mayo Clinic Glial Autoimmunity Study: AQP4/MOG-IgG serostatus and outcomes in 228 patients presenting with recurrent optic neuritis (S13.007) (2018) (0)
Advances in myasthenia gravis, proceedings of the myasthenia gravis foundation medical advisory board, New York, NY, December 4, 1981 (1982) (0)
Autoantibody (anti‐Hu) seronegativity (1994) (0)
Daytime Polysomnography Recording in LIG1 -Related Limbic Encephalitis—Reply (2012) (0)
Adult-Onset Autoimmune Chorea (S08.003) (2012) (0)
Reply: Autoantibody (Anti–Hu) seronegativity (1994) (0)
A distinctive IgG-mediated pathogenesis for primary progressive multiple sclerosis? (2023) (0)
Neuromyelitis Optica Spectrum Disorders, Immunology of (2014) (0)
An Autoimmune Basis for Diabetes-Related Chorea? (2016) (0)
Hydrocephalus in Neuromyelitis Optica (P2.270) (2014) (0)
Aquaporin-4 autoantibodies define autoimmune optic neuritis (2008) (0)
Re: Paraneoplastic antibodies (1995) (0)
Voltage-dependent Ca2+ influx by human small cell carcinomas (SCC) is impaired by Ig from Lambert-eaton myasthenic syndrome (LES) (1987) (0)
Neuromuscular Disorders and Techniques : Novel Observations and Fresh Looks Faculty (2006) (0)
Prolonged QTc Interval in Patients Seropositive for Ganglionic (α-3) Acetylcholine Receptor Autoantibody (P1.274) (2015) (0)
Synthetic. cap alpha. subunit peptide 125-147 of human nicotinic acetylcholine receptor induces antibodies to native receptor (1986) (0)
Characterization of inherited canine myasthenia gravis (1983) (0)
SERA OF MICE HYPERIMMUNIZED WITH MYELIN COMPONENTS PROMOTE CNS REMYELINATION IN CHRONIC THEILERʼS VIRUS ENCEPHALOMYELITIS (1985) (0)
Experimental autoimmune myasthenia gravis (eamg) in mice: role of ia molecule. Abstr. (1981) (0)
ANTIGENIC PROPERTIES OF MYELIN CONSTITUENTS AND SHEATH CELLS: 82 (1979) (0)
The Mayo Clinic Glial Autoimmunity Study: Glial autoantibody (AQP4/MOG/GFAP) serostatus in recurrent longitudinally extensive transverse myelitis (P6.409) (2018) (0)
PO27-TH-14 Spinocerebellar atrophy, total deafness, sensory neuronopathy and a de novo neuronal cytoplasmic antibody (2009) (0)
Comparison of Bromcresol Purple and Capillary Protein Electrophoresis for Quantification of Serum Albumin in Multiple Myeloma (2009) (0)
Pathogenic monoclonal antibodies define 2 regions of nicotinic acetylcholine receptor (AChR) distinct from cholinergic ligand site (1980) (0)
Evangelos Giannitsis 2* Aqp4-igg Immunoprecipitation Assay Optimization (2009) (0)
104. Broad clinical spectrum of voltage-gated gotassium channel autoimmunity (2009) (0)
T cell stimulatory and myasthenogenic regions in human skeletal muscle acetylcholine receptor (AChR) α subunit (1991) (0)
101. Asymptomatic Lambert–Eaton myasthenic syndrome (2009) (0)
News Items / Erratum (1972) (0)
Marker of neuromyelitis optica (2004) (0)
The Stiff Child (IN1-1.004) (2013) (0)
A Case of Idiopathic Autoimmune Gastrointestinal Dysmotility: 606 (2005) (0)
Paediatric autoimmune encephalopathies: a lot done, more to do (2012) (0)
315. High voltage-activated calcium channels: Review and implications for mental illness (1996) (0)
Neuronal autoantibodies excite guinea pig myenteric neurons (2010) (0)
Erratum: Bilateral autoimmune optic neuritis and vitreitis related to CRMP-5-IgG: Intravitreal triamcinolone acetonide therapy of four eyes (Eye (2008) 22 (1191-1193) DOI:10.1038/sj.eye.6702959) (2009) (0)
Anti-synaptic autoimmunity: An emerging clinical entity (1991) (0)
Prospective Evaluation of Maintenance Plasma Exchange (mPLEX) for Attack Prevention in Neuromyelitis Optica Spectrum Disorder: Preliminary Feasibility, Safety, and Efficacy Data (P5.265) (2015) (0)
FP45-TH-05 Signal recognition particle antibodies define an autoimmune myopathy spectrum (2009) (0)
Synthesis of an antigenic site of native acetylcholine receptor (AChR) alpha chain: Peptide α159-169 (1985) (0)
Reply (2001) (0)
Clinical utility of testing cerebrospinal fluid (CSF) for AQP4-IgG: A guideline to improve physician ordering of AQP4-IgG diagnostic test. (S12.003) (2016) (0)
Antigenic requirements for induction of hyperacute EAE (1975) (0)
Bulbar-Predominant Weakness (2021) (0)
What Is the Frequency of “Truly” AQP4-IgG-Negative NMO and Does It Differ Phenotypically from Seropositive Disease? (P02.136) (2013) (0)
Case Control Analysis of Glycine Receptor Autoimmunity (P5.125) (2017) (0)
Autoimmune Cerebellar Ataxia: Treatment Responses and Outcomes in 118 Patients (I4-4B) (2015) (0)
Glucocorticoid Regulation of Ependymal Glia and Regenerative Potential after Spinal Cord Injury (2018) (0)
003 Autoimmune encephalitis antibody biomarkers: frequency, age and sex associations (2021) (0)
Progressive Autoimmune Neuromyotonia with Low Voltage-Gated Potassium Channel-Complex IgG and CASPR2-IgG Following Remote Inflammatory Polyradiculoneuropathy (P4.019) (2015) (0)
Letter: Experimental arthritis in thymectomized rats with an impaired humoral immune response. (1973) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Vanda Alice Lennon?

Vanda Alice Lennon is affiliated with the following schools:

Vanda Alice Lennon's Academic­Influence.com Rankings